Newbridge Financial Services Group’s Mereo BioPharma MREO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.19K Buy
18,750
+1,750
+10% +$751 ﹤0.01% 876
2025
Q4
$7.08K Buy
17,000
+4,000
+31% +$7.61K ﹤0.01% 839
2025
Q3
$26.8K Hold
13,000
﹤0.01% 670
2025
Q2
$35.2K Buy
13,000
+2,000
+18% +$4.83K 0.01% 578
2025
Q1
$24.8K Buy
11,000
+300
+3% +$849 0.01% 499
2024
Q4
$37.5K Buy
+10,700
New +$42K 0.01% 472
2024
Q3
Sell
-11,700
Closed -$42.1K 935
2024
Q2
$42.1K Hold
11,700
0.02% 406
2024
Q1
$38.6K Buy
11,700
+2,200
+23% +$7.45K 0.02% 449
2023
Q4
$21.9K Buy
+9,500
New +$18.2K 0.01% 574
2023
Q3
Sell
-9,500
Closed -$12.5K 1368
2023
Q2
$12.5K Buy
9,500
+2,500
+36% +$2.9K 0.01% 836
2023
Q1
$4.95K Buy
7,000
+3,000
+75% +$2.7K ﹤0.01% 1072
2022
Q4
$3K Hold
4,000
﹤0.01% 1154
2022
Q3
$3K Hold
4,000
﹤0.01% 1138
2022
Q2
$4K Hold
4,000
﹤0.01% 1059
2022
Q1
$4K Hold
4,000
﹤0.01% 1149
2021
Q4
$6K Hold
4,000
﹤0.01% 1034
2021
Q3
$10K Hold
4,000
0.01% 870
2021
Q2
$13K Hold
4,000
0.01% 910
2021
Q1
$13K Buy
+4,000
New +$14.1K 0.01% 824

Other funds holding MREO

Newbridge Financial Services Group's MREO Position: Q1 2026 in Review

Newbridge Financial Services Group increased its Mereo BioPharma (MREO) stake by 10% in Q1 2026, buying an estimated $751 and bringing the position to 18,750 shares worth $6.19K. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Newbridge Financial Services Group first reported a position in MREO in Q1 2021 and has held it in 19 quarters since. The position peaked at $42.1K in Q2 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Newbridge Financial Services Group held 18,750 shares of Mereo BioPharma worth $6.19K as of Q1 2026.
  • Newbridge Financial Services Group bought 1,750 Mereo BioPharma shares in Q1 2026, an estimated $751.
  • Mereo BioPharma made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #876 holding.
  • Newbridge Financial Services Group first reported a position in Mereo BioPharma in Q1 2021 and has held it in 19 quarters since.
  • Newbridge Financial Services Group's Mereo BioPharma position peaked at $42.1K in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.